Securities Science, Computers & Technology Business Torts

SEC Insider Trading Class Action Fraud Virtual Currency Bitcoins Pharmaceutical Securities Fraud CFTC Enforcement Enforcement Actions Life Sciences Popular Clinical Trials Cybersecurity Material Nonpublic Information Pharmaceutical Manufacturers Securities Act of 1933 Shareholders Amgen Inc. v Connecticut Retirement Plans Disclosure Requirements FDA FinCEN FINRA Fraud-on-the-Market High Frequency Trading Investors Medical Devices Ponzi Scheme Public Offerings SCOTUS Securities Securities Exchange Act Shareholder Litigation Administrative Hearings Algorithmic Trading Amgen Attorney-Client Privilege Auditors Audits Australia Australian Securities and Investments Commission Best Management Practices BioMimetic Therapeutics Biopharmaceutical Biotechnology C-Suite Executives CEOs Chief Compliance Officers Citigroup Civil Monetary Penalty Class Certification Cloud Computing Compliance Confidential Information Confidentiality Corporate Officers Corruption Criminal Prosecution Crowdfunding Cryptocurrency Data Breach Data Protection Deficiency Notices Derivative Suit Directors Distributors Dodd-Frank DOJ Drug Manufacturers Duty to Disclose Emerging Trading Technologies Ethics Family Members FATF FSOC FTC Funding Portal G20 Genta Genzyme Global Bitcoin Stock Exchange Healthcare Injunctions InterMune Investigations Investor Protection JOBS Act Lying MAI Marketing Martoma Mary Jo White Material Disclosures Material Misstatements Materiality Misrepresentation NFA Off-Label Promotion Offerings OIA Omnicare ORC Prejudgment Interest PSLRA Publicly-Traded Companies Pyramid Schemes Risk Assessment Risk Management Risk Mitigation Rule 10b-5 Surveys U.S. Treasury Websites Whistleblower Awards Whistleblowers Wyndham